Key FDA Decisions and Trial Results Coming in the Next 2 Months
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 197
Jefferies Issues Top Pharma and Biohealth Stocks to Buy
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
Major Pharma Continues to See Significant Drop in Short Interest
The August 31 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
Short Sellers Run for Cover From Major Biotechs
The August 31 short interest data have been compared with the previous report, and short interest decreased for most of these selected biotech stocks.
Is Geron Being Overly Punished?
Investors never like to see a stock they own drop 17%, but there is at least one view that maybe the drop is an opportunity for those with longer-term views who remain bullish.
The 25 States Where Medical Marijuana Is Legal
It is presumed that states where medical marijuana is legal will be the most likely to have laws that provide for recreational use.
Why Horizon Pharma Is Not Overpaying for Raptor Pharma
If we look at what Horizon is paying, it doesn’t necessarily add up, using the numbers from this year, but if we look at more data the picture becomes clearer.
4 Key BioPharma Movers in the Past Week
Some biotech companies made impressive runs over the course of this past week. These select few stood out from the rest.
How Obesity and Smoking Add $142 Billion to US Health Care Costs Annually
The primary conclusion of a recent study about the cost of obesity and smoking in America is that they add $142 billion each year in incremental health care costs.
Why Lexicon Pharma Is Soaring
Lexicon Pharmaceuticals rallied Friday on late-stage results from a pivotal Phase 3 clinical trial of a type 1 diabetes treatment.
American Heath Deteriorated During Obama Administration
The most recent Gallup-Healthways study shows that well-being in the United States dropped during the Obama administration.
Why Repros Is Rising
Shares of Repros Therapeutics climbed in Thursday’s session after the company announced results from its mid-stage study for women with moderate to severe confirmed endometriosis.
Evaluating a GW Pharma Merger, Maybe
24/7 Wall St. has been concerned about the longer-term implications of GW Pharma over other emerging drug and biotech outfits.
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These catalyst events can make or break these companies.
Did Agios Just Speed Up Its Business Plan by 2 Years?
Celgene is making a move out of left field that has sent shares of its partner Agios Pharmaceuticals significantly higher.